• LAST PRICE
    3.0300
  • TODAY'S CHANGE (%)
    Trending Down-0.2900 (-8.7349%)
  • Bid / Lots
    3.0200/ 10
  • Ask / Lots
    3.0300/ 10
  • Open / Previous Close
    3.3000 / 3.3200
  • Day Range
    Low 2.9500
    High 3.3000
  • 52 Week Range
    Low 2.8650
    High 13.7000
  • Volume
    1,016,558
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.32
TimeVolumeFULC
09:32 ET178343.25
09:35 ET76983.16
09:37 ET8363.15
09:39 ET4863.1495
09:44 ET4003.15
09:46 ET3003.1401
09:48 ET22003.13
09:50 ET28003.13
09:51 ET14373.14
09:53 ET74753.1499
09:55 ET36843.145
09:57 ET2003.15
10:02 ET26303.115
10:04 ET41423.1264
10:06 ET20103.125
10:08 ET5173.12
10:09 ET157673.11
10:11 ET18653.11
10:13 ET22703.095
10:15 ET21303.1
10:18 ET18793.095
10:20 ET25713.095
10:22 ET44063.095
10:24 ET116373.0899
10:26 ET24993.09
10:27 ET6003.095
10:29 ET126943.105
10:31 ET2003.09
10:33 ET30933.085
10:36 ET400863.045
10:38 ET140203.045
10:40 ET99143.055
10:42 ET34713.06
10:44 ET49033.045
10:45 ET2003.045
10:47 ET44453.04
10:49 ET17063.035
10:51 ET14003.035
10:54 ET214813.0298
10:56 ET55453.01
10:58 ET28273.015
11:00 ET333733.045
11:02 ET438933.0184
11:03 ET241423.005
11:05 ET120753.005
11:07 ET214933
11:09 ET25093.01
11:12 ET49313.0001
11:14 ET16893.02
11:16 ET78003.045
11:18 ET50973.07
11:20 ET13303.07
11:21 ET248763.075
11:23 ET35703.08
11:25 ET9663.075
11:27 ET8113.07
11:30 ET790843.075
11:32 ET631413.075
11:34 ET4003.0698
11:36 ET733823.035
11:38 ET114963.01
11:39 ET36673.005
11:41 ET110533
11:43 ET14982.99
11:45 ET27072.995
11:48 ET44942.995
11:50 ET7652.985
11:52 ET1002.985
11:54 ET94502.99
11:56 ET22002.985
11:59 ET3002.985
12:01 ET127042.98
12:03 ET106712.975
12:06 ET11972.975
12:08 ET29982.96
12:10 ET53602.955
12:12 ET102242.9501
12:14 ET56842.975
12:15 ET25002.98
12:17 ET21412.985
12:19 ET34002.985
12:21 ET18852.965
12:24 ET114772.965
12:26 ET78662.965
12:28 ET4002.9689
12:30 ET8012.965
12:32 ET3522.96
12:33 ET32932.96
12:35 ET2002.96
12:37 ET1002.97
12:39 ET9002.965
12:42 ET4632.9675
12:46 ET15172.965
12:48 ET2002.965
12:50 ET174782.965
12:51 ET19722.985
12:53 ET3002.985
12:57 ET2002.9897
01:00 ET28012.975
01:02 ET16522.975
01:04 ET9422.98
01:06 ET15002.975
01:08 ET32082.98
01:09 ET9382.99
01:11 ET28003
01:13 ET1003
01:15 ET3002.995
01:18 ET46842.995
01:20 ET15632.985
01:22 ET104002.9899
01:24 ET28202.985
01:26 ET39002.99
01:27 ET66523.015
01:29 ET2003.02
01:31 ET1003.015
01:33 ET9833.03
01:36 ET6643.02
01:38 ET1143.025
01:40 ET6283.02
01:42 ET9893.02
01:44 ET9143.015
01:45 ET14163.01
01:47 ET2003.02
01:49 ET31123.0101
01:56 ET15903.01
01:58 ET8003.02
02:00 ET5003.01
02:02 ET12823.015
02:03 ET7003.015
02:05 ET25513.01
02:07 ET3003.02
02:12 ET5003.015
02:14 ET5273.02
02:16 ET2003.015
02:18 ET25863.01
02:20 ET2003.015
02:21 ET16453.005
02:23 ET10963
02:25 ET6003.005
02:27 ET4003.005
02:30 ET2003.005
02:32 ET29003.005
02:34 ET39003.015
02:36 ET11853.015
02:38 ET28493.03
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesFULC
Fulcrum Therapeutics Inc
207.2M
-9.8x
---
United StatesINBX
Inhibrx Biosciences Inc
207.4M
0.1x
---
United StatesKYTX
Kyverna Therapeutics Inc
207.1M
0.0x
---
United StatesBNTC
Benitec Biopharma Inc
206.1M
-1.4x
---
United StatesHURA
TuHURA Biosciences Inc
205.9M
-0.1x
---
United StatesIMMP
Immutep Ltd
320.7M
-9.0x
---
As of 2024-11-15

Company Information

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Contact Information

Headquarters
26 Landsdowne StreetCAMBRIDGE, MA, United States 02139
Phone
617-651-8851
Fax
302-655-5049

Executives

Independent Chairman of the Board
Kate Haviland
President, Chief Executive Officer, Director
Alex Sapir
Chief Financial Officer, Treasurer
Alan Musso
Executive Vice President - Patient Affairs
Mel Hayes
Chief Regulatory Affairs and Quality Assurance Officer
Heather Faulds

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$207.2M
Revenue (TTM)
$80.9M
Shares Outstanding
62.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.10
EPS
$-0.31
Book Value
$3.80
P/E Ratio
-9.8x
Price/Sales (TTM)
2.6
Price/Cash Flow (TTM)
---
Operating Margin
-37.66%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.